Three publications published during the summer of 2024 report the use of efgartigimod (Vyvgart®), a neonatal anti-Fc receptor (FcRn), to treat acute decompensations of autoimmune myasthenia:
- these case reports from Japan and China concern a total of 14 patients aged between 26 and 76, with anti-RACh (13 cases) or anti-MuSK;
- efgartigimod contributed to the rapid resolution of myasthenic attacks, even in cases of resistance to intravenous immunoglobulin.
These results have yet to be confirmed by large-scale studies. In the meantime, they suggest that efgartigimod could be a fast-acting and effective treatment for myasthenic attacks.
